PT  - JOURNAL ARTICLE
AU  - Chiu, Ricky Y. T.
AU  - Kojima, Noah
AU  - Mosley, Garrett Lee
AU  - Cheng, Kwok Kin
AU  - Pereira, David Y.
AU  - Brobeck, Matthew
AU  - Chan, Tsun Leung
AU  - Zee, Jonpaul Sze-Tsing
AU  - Kittur, Harsha
AU  - Chung, Tenny Cheuk-Yiu
AU  - Tsang, Eric
AU  - Maran, Kajal
AU  - Yung, Raymond Wai-Hung
AU  - Leung, Alex Chin-Pang
AU  - Siu, Ryan Ho-Ping
AU  - Ng, Jessica Pui-Ling
AU  - Choi, Tsz Hei
AU  - Fung, Mei Wai
AU  - Chan, Wai Sing
AU  - Lam, Ho Yin
AU  - Lee, Koon Hung
AU  - Parkin, Sean
AU  - Chao, Felix C.
AU  - Ho, Stephen Ka-Nung
AU  - Marshak, Daniel R.
AU  - Ma, Edmond Shiu-Kwan
AU  - Klausner, Jeffrey D.
TI  - Evaluation of the INDICAID™ COVID-19 Rapid Antigen Test in symptomatic populations and asymptomatic community testing
AID  - 10.1101/2021.05.26.21257063
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.26.21257063
4099  - http://medrxiv.org/content/early/2021/06/02/2021.05.26.21257063.short
4100  - http://medrxiv.org/content/early/2021/06/02/2021.05.26.21257063.full
AB  - Background As the COVID-19 pandemic continues to cause substantial morbidity and mortality, there is an increased need for rapid, accessible assays for SARS-CoV-2 detection.Methods Here we present a clinical evaluation and real-world implementation of the INDICAID™ COVID-19 Rapid Antigen Test (INDICAID™ Rapid Test). A multi-site clinical evaluation of the INDICAID™ Rapid Test using prospectively collected samples from symptomatic subjects was performed. The INDICAID™ Rapid Test was then implemented at COVID-19 outbreak screening centers in Hong Kong to screen individuals for COVID-19 to prioritize confirmatory RT-PCR testing among asymptomatic populations.Results The clinical evaluation in symptomatic patient populations demonstrated a positive percent agreement and negative percent agreement of 85.3% (95% confidence interval [95% CI]: 75.6% - 91.6%) and 94.9% (95% CI: 91.6% - 96.9%), respectively, when compared to laboratory-based RT-PCR testing. When used during outbreak testing of 22,994 asymptomatic patients, the INDICAID™ Rapid Test demonstrated a positive percent agreement of 84.2% (95% CI: 69.6% - 92.6%) and a negative percent agreement of 99.9% (95% CI: 99.9% - 100%) compared to laboratory-based RT-PCR testing. When incorporated in a testing algorithm, the INDICAID™ Rapid Test reduced time to confirmatory positive result from an average 10.85 hours (standard RT-PCR only) to 0.84 hours, depending on the algorithm.Conclusion The INDICAID™ Rapid Test has excellent performance when compared to laboratory-based RT-PCR testing, and when used in tandem with RT-PCR, reduces the time to confirmatory positive result.Summary In clinical evaluations, the INDICAID™ COVID-19 Rapid Antigen Test demonstrated high sensitivity and specificity in symptomatic and asymptomatic patient populations. When used in tandem with RT-PCR testing, the INDICAID™ Rapid Test expedited confirmatory results and may help reduce SARS-CoV-2 outbreaks.Competing Interest StatementR.C., G.L.M., K.K.C., D.Y.P., H.K., T.C.C., E.T., K.M., R.H.S., J.P.N., T.H.C., M.W.F., F.C.C., D.R.M., and J.K. all have an equity interest and employment with Phase Scientific International Ltd.Clinical TrialNCT04904510Funding StatementSelf-fundedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:To protect the rights, safety, and welfare of subjects, the study was conducted in accordance with 21 CFR 50, Protection of Human Subjects. Prior to study enrollment, each subject was asked to voluntarily provide his or her oral consent after being provided the IRB-approved Research Information Sheet. The onsite study investigator explained the nature, purpose, expected duration, and risks of study participation. Each potential subject had the opportunity to ask questions and receive answers from personnel conducting the study. All subjects were provided a copy of the Research Information Sheet. The IRB was reviewed by Advarra, IRB number: Pro00047510.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available by request if requests are reasonable.